412 related articles for article (PubMed ID: 25974377)
1. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis.
Santarpia G; De Rosa S; Polimeni A; Giampà S; Micieli M; Curcio A; Indolfi C
PLoS One; 2015; 10(5):e0126512. PubMed ID: 25974377
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of nonvitamin K antagonist oral anticoagulants during catheter ablation of atrial fibrillation: A systematic review and meta-analysis.
Ge Z; Faggioni M; Baber U; Sartori S; Sorrentino S; Farhan S; Chandrasekhar J; Vogel B; Qadeer A; Halperin J; Reddy V; Dukkipati S; Dangas G; Mehran R
Cardiovasc Ther; 2018 Oct; 36(5):e12457. PubMed ID: 29971964
[TBL] [Abstract][Full Text] [Related]
3. An updated meta-analysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation.
Cardoso R; Knijnik L; Bhonsale A; Miller J; Nasi G; Rivera M; Blumer V; Calkins H
Heart Rhythm; 2018 Jan; 15(1):107-115. PubMed ID: 28917562
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis of randomized controlled trials of uninterrupted periprocedural anticoagulation strategy in patients undergoing atrial fibrillation catheter ablation.
Zhao Y; Lu Y; Qin Y
Int J Cardiol; 2018 Nov; 270():167-171. PubMed ID: 29903520
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation.
Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH
Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384
[TBL] [Abstract][Full Text] [Related]
6. Uninterrupted anticoagulation with non-vitamin K antagonist oral anticoagulants in atrial fibrillation catheter ablation: Lessons learned from randomized trials.
Cardoso R; Willems S; Gerstenfeld EP; Verma A; Schilling R; Hohnloser SH; Okumura K; Nordaby M; Brouwer MA; Calkins H
Clin Cardiol; 2019 Jan; 42(1):198-205. PubMed ID: 30460702
[TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis of Safety and Efficacy of Uninterrupted Non-Vitamin K Antagonist Oral Anticoagulants Versus Vitamin K Antagonists for Catheter Ablation of Atrial Fibrillation.
Elgendy AY; Mahtta D; Barakat AF; Abuzaid A; Mahmoud A; Mentias A; Mahmoud AN; Elgendy IY
Am J Cardiol; 2017 Nov; 120(10):1830-1836. PubMed ID: 28882334
[TBL] [Abstract][Full Text] [Related]
8. Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.
Bawazeer GA; Alkofide HA; Alsharafi AA; Babakr NO; Altorkistani AM; Kashour TS; Miligkos M; AlFaleh KM; Al-Ansary LA
Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013504. PubMed ID: 34674223
[TBL] [Abstract][Full Text] [Related]
9. Interrupted or Uninterrupted Oral Anticoagulants in Patients Undergoing Atrial Fibrillation Ablation.
Yang P; Wang C; Ye Y; Huang T; Yang S; Shen W; Xu G; Wu Q
Cardiovasc Drugs Ther; 2020 Jun; 34(3):371-381. PubMed ID: 32232617
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
[TBL] [Abstract][Full Text] [Related]
11. Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis.
Nairooz R; Ayoub K; Sardar P; Payne J; Almomani A; Pothineni NV; Shailesh F; Aronow WS; Mukherjee D
Can J Cardiol; 2016 Jun; 32(6):814-23. PubMed ID: 26810476
[TBL] [Abstract][Full Text] [Related]
12. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
13. Comparison of major bleeding events of uninterrupted non-vitamin K antagonist oral anticoagulants versus uninterrupted vitamin K antagonist during catheter ablation of atrial fibrillation: a meta-analysis of randomised controlled trials.
Yang Q; Chen X; Zhai J; Dang Y
Acta Cardiol; 2022 May; 77(3):257-263. PubMed ID: 33871328
[TBL] [Abstract][Full Text] [Related]
14. Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation.
Patti G; Pecen L; Lucerna M; Huber K; Rohla M; Renda G; Siller-Matula J; Ricci F; Kirchhof P; De Caterina R
Am J Med; 2019 Jun; 132(6):749-757.e5. PubMed ID: 30664837
[TBL] [Abstract][Full Text] [Related]
15. Influence of periprocedural anticoagulation strategies on complication rate and hospital stay in patients undergoing catheter ablation for persistent atrial fibrillation.
Gunawardene M; Willems S; Schäffer B; Moser J; Akbulak RÖ; Jularic M; Eickholt C; Nührich J; Meyer C; Kuklik P; Sehner S; Czerner V; Hoffmann BA
Clin Res Cardiol; 2017 Jan; 106(1):38-48. PubMed ID: 27435077
[TBL] [Abstract][Full Text] [Related]
16. Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter Ablation of Atrial Fibrillation.
Romero J; Cerrud-Rodriguez RC; Alviz I; Diaz JC; Rodriguez D; Arshad S; Cerna L; Taveras J; Grupposo V; Natale A; Garcia M; Di Biase L
JACC Clin Electrophysiol; 2019 Dec; 5(12):1396-1405. PubMed ID: 31857038
[TBL] [Abstract][Full Text] [Related]
17. The Risk of Gastrointestinal Bleeding between Non-Vitamin K Antagonist Oral Anticoagulants and Vitamin K Antagonists in the Asian Atrial Fibrillation Patients: A Meta-Analysis.
Yang KT; Sun WC; Tsai TJ; Tsay FW; Chen WC; Cheng JS
Int J Environ Res Public Health; 2020 Dec; 18(1):. PubMed ID: 33375495
[No Abstract] [Full Text] [Related]
18. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation.
Briere JB; Bowrin K; Millier A; Toumi M; Wojciechowski P; Taieb V
J Med Econ; 2019 Aug; 22(8):760-765. PubMed ID: 30969801
[No Abstract] [Full Text] [Related]
19. Thromboembolism and bleeding risk in atrial fibrillation ablation with uninterrupted anticoagulation between new oral anticoagulants and vitamin K antagonists: insights from an updated meta-analysis.
Liu XH; Gao XF; Chen CF; Chen B; Xu YZ
J Thromb Thrombolysis; 2020 Jul; 50(1):201-210. PubMed ID: 31686297
[TBL] [Abstract][Full Text] [Related]
20. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]